Five Prime Therapeutics, Inc. Patent applications |
Patent application number | Title | Published |
20140322757 | ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. | 10-30-2014 |
20140274898 | HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMAINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 09-18-2014 |
20140170145 | COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT - Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss. | 06-19-2014 |
20140140995 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 05-22-2014 |
20140086840 | Therapeutic Antibody Target Validation and Screening In Vivo - An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided. | 03-27-2014 |
20140079699 | METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis. | 03-20-2014 |
20140056891 | TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS - The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation. | 02-27-2014 |
20130324701 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 12-05-2013 |
20130189262 | IL-27 Antagonists for Treating Inflammatory Diseases - Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA. | 07-25-2013 |
20130065276 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 03-14-2013 |
20130058928 | HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 03-07-2013 |
20120301921 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 11-29-2012 |
20120219524 | ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. | 08-30-2012 |
20120183548 | IL-27 Antagonists for Treating Inflammatory Diseases - Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA. | 07-19-2012 |
20120183477 | Therapeutic Antibody Target Validation and Screening In Vivo - An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided. | 07-19-2012 |
20120003222 | FZD8 EXTRACELLULAR DOMAINS AND FZD8 EXTRACELLULAR DOMAIN FUSION MOLECULES AND TREATMENTS USING SAME - Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided. | 01-05-2012 |
20110288024 | Compositions and Methods for Treating Arthritis and/or Diseases Involving Cartilage Degeneration - The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided. | 11-24-2011 |
20110274683 | Antibodies That Bind CSF1R - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. | 11-10-2011 |
20100324270 | Compositions and Methods of Use for Modulators of Polypeptides and Polynucleotides in Treating Breast Cancer and Melanoma - This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders. | 12-23-2010 |
20100210829 | Compositions and Methods for Treating Diseases, Disorders, or Conditions Characterized by Myelin Degeneration, Myelin Deficiency or Loss - Provided herein are novel polypeptides, polynucleotides and compositions containing such, and to methods useful in treating diseases, disorders, or conditions of the central nervous system (CNS) associated with demyelination. The novel polypeptides, polynucleotides stimulate oligodendrocyte precursor cell (OPC), and are capable of promoting myelination or remyelination in a subject. | 08-19-2010 |
20100062009 | NOVEL STROMAL CELL-DERIVED FACTOR-1 POLYPEPTIDES, POLYNUCLEOTIDES, MODULATORS THEREOF AND METHODS OF USE - Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases. | 03-11-2010 |
20090010946 | Novel Stromal Cell-Derived Factor-1 Polypeptides, Polynucleotides, Modulators Thereof and Methods of Use - Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases. | 01-08-2009 |